NS Pharma’s Duchenne Muscular Dystrophy Therapy Viltepso Fails Confirmatory Trial

1. Trial Failure: NS Pharma's Duchenne muscular dystrophy therapy Viltepso failed its confirmatory Phase III RACER53 study, casting doubt on its future.
2. Study Details: The study evaluated the efficacy and safety of Viltepso at an 80 mg/kg once weekly dosing versus placebo for 48 weeks.
3. FDA Approval: The failure of the confirmatory trial puts Viltepso's 2020 accelerated FDA approval in jeopardy.
4. Company Response: Despite the failure, NS Pharma is keeping faith in Viltepso and will continue to explore its potential.
5. Impact: The failure of Viltepso raises concerns about the future of Nippon Shinyaku's Duchenne muscular dystrophy therapy.